Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HNF4A | P41235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645979 | 0.78 | HTT (0.44) | GRM5ASIC3APPGRM4FFAR1 | |
| SCHEMBL21645953 | 0.78 | HTT (0.44) | GRM5ASIC3APPGRM4FFAR1 | |
| SCHEMBL29951370 | 0.76 | HDAC8 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL481107 | 0.76 | CLK4 (0.39) | GRM4CA1CA2 | |
| SCHEMBL29956567 | 0.76 | CLK4 (0.39) | GRM4CA1CA2 | |
| SCHEMBL28536669 | 0.73 | FFAR1 (0.47) | GRM5APPFFAR1 | |
| SCHEMBL2107128 | 0.73 | GRM5 (0.46) | GRM5ASIC3APPGRM4FFAR1 | |
| SCHEMBL23918702 | 0.72 | FFAR1 (0.56) | GRM5ASIC3APPGRM4FFAR1 | |
| SCHEMBL2084619 | 0.72 | EGFR (0.45) | ASIC3ERN1 | |
| SCHEMBL16139763 | 0.72 | GRM5 (0.57) | GRM5ASIC3APPGRM4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | claimed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | claimed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | claimed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | claimed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| US-12065409-B2 | Analogs of 2-pralidoxime as antidotes against organophosphorus nerve agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-08-20 | — | — | US | disclosed |
| US-20210317084-A1 | Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-14 | — | — | US | disclosed |
| WO-2020027905-A2 | ANALOGS OF 2-PRALIDOXIME AS ANTIDOTES AGAINST ORGANOPHOSPHORUS NERVE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-02-06 | — | — | WO | disclosed |
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | GRM5 1591/4885ASIC3 737/4885APP 2189/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | GRM5 1591/4885ASIC3 737/4885APP 2189/4885 |
| US-20210317084-A1 | Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents | ACHE, DDT, BCHE | GRM5 2463/4885ASIC3 4367/4885APP 667/4885 |
| US-12065409-B2 | Analogs of 2-pralidoxime as antidotes against organophosphorus nerve agents | ACHE, DDT, BCHE | GRM5 2463/4885ASIC3 4367/4885APP 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.